SPORE in Prostate Cancer

描述(由申请人提供)： 这项申请代表着前列腺癌专业卓越研究计划(SPORT)的创建，该计划源于新配置的Dana-Farber哈佛癌症中心(DF/HCC)的前列腺癌计划。DF/HCC前列腺癌孢子包括来自所有哈佛附属医院、贝丝以色列女执事医院、布里格姆妇女医院、达纳-法伯癌症研究所、马萨诸塞州总医院和哈佛大学公共卫生学院的研究人员。该应用程序支持五个主要项目，包括：1)PI3/Kinase的遗传和血清学标记 AKT途径在前列腺癌中的作用；2)作为前列腺癌治疗靶点的过氧化物酶体增殖物激活物受体γ；3)前列腺癌的基因分类；4)前列腺癌预后的表达分析；以及5)激素非依赖性前列腺癌中的雄激素受体。这些项目将通过创建四个核心来整合。它们是：1)管理、评估和规划；2)生物统计学；3)组织和病理学；4)基因组学。这份孢子申请概述了一项发展项目计划，其中包括一项选择新项目的计划以及七个可能是 支持。我们还包括一个职业发展奖励计划，该计划概述了一种识别和支持前列腺癌领域有才华的年轻研究人员的机制。DFCC孢子的总体目标是将生物和技术进步转化为对前列腺癌男性有临床意义的进步。

DESCRIPTION (provided by applicant): This application represents the creation of a Specialized Program of Research Excellence (SPORE) in Prostate Cancer originating from the Prostate Cancer Program of the newly configured Dana-Farber Harvard Cancer Center (DF/HCC). The DF/HCC Prostate Cancer SPORE includes investigators from all the Harvard affiliated hospitals; The Beth Israel Deaconess Hospital, the Brigham & Women's Hospital, the Dana-Farber Cancer Institute, the Massachusetts General Hospital, and the Harvard School of Public Health. Five major projects are supported through this application including: 1) Genetic and serological markers of the PI3/Kinase Akt pathway in prostate cancer; 2) the peroxisome proliferator activator receptor gamma as a target for prostate cancer therapy; 3) the genetic classification of prostate cancer; 4) Expression analysis prediction of prostate cancer outcome; and 5) the androgen receptor in hormone refractory prostate cancer. These projects will be integrated by the creation of four cores. These are: 1) Administration, evaluation, and planning; 2) Biostatistics; 3) Tissue and Pathology; and 4) Genomics. This SPORE application outlines a Developmental Projects Program that includes a plan for selection of new projects as well as seven pilot projects that could be supported. We also include a Career Development Award Program that outlines a mechanism for the identification and support of talented young investigators in prostate cancer. The overall goal of the DFHCC SPORE is the translation of biological and technological advances into clinically meaningful advances for men with prostate cancer.